Chronic analgesic suppression of nociceptor‑derived CGRP lowers systemic NAD+ and blunts SIRT1‑mediated mitohormesis, accelerating cellular aging

Ageless Mike· Mar 26, 2026

Mechanism: Chronic analgesic use inhibits nociceptor-derived CGRP, which normally stimulates NAD+ biosynthesis via NAMPT and fuels SIRT1-mediated mitohormesis. Readout: Readout: This leads to lower plasma NAD+ levels, reduced SIRT1 activity, increased p16^INK4a^ senescence markers, and a reduced healthspan.

Hypothesis

Persistent pharmacological silencing of nociceptive signaling—particularly via TRPV1‑dependent pathways—reduces the release of calcitonin gene‑related peptide (CGRP) from sensory neurons. CGRP normally stimulates NAD+ biosynthesis in resident macrophages and endothelial cells through activation of the NAMPT enzyme. Lower NAD+ diminishes SIRT1 deacetylase activity, weakening the hormetic activation of mitochondrial unfolded‑protein response (UPRmt), autophagy, and DNA‑repair pathways that are triggered by low‑grade inflammatory stress. Consequently, long‑term analgesic use converts a protective, pain‑evoked mitohormetic signal into a chronic NAD+ deficit, promoting senescence‑associated phenotypes and shortening healthspan.

Mechanistic Rationale

Nociceptor‑CGRP‑NAD+ Axis – Injured or inflamed tissue activates TRPV1+ sensory neurons, triggering CGRP release. CGRP binds its receptor (RAMP1/CLR) on perivascular macrophages, elevating intracellular cAMP and stimulating NAMPT‑mediated NAD+ salvage (see [1] for CGRP‑immune modulation).
NAD+‑SIRT1 Mitohormesis – NAD+ fuels SIRT1, which deacetylates PGC‑1α, FOXO3a, and NF‑κB, promoting mitochondrial biogenesis, antioxidant defenses, and autophagy—core effectors of mild stress‑induced hormesis ([6]).
Analgesic Interruption – NSAIDs inhibit COX‑derived prostaglandins that sensitize TRPV1; opioids directly inhibit neuronal excitability. Both blunt CGRP efflux ([2],[4]), thereby decreasing macrophage NAD+ production.
Outcome – Reduced SIRT1 activity leads to accumulated acetyl‑p53, diminished FOXO‑driven stress resistance, and impaired mitophagy, driving cellular senescence and inflammaging ([3],[5]).

Testable Predictions

In vivo: Mice with sensory‑neuron‑specific TRPV1 deletion (Nav1.8‑Cre;Trpv1^fl/fl) will show lower plasma NAD+, reduced SIRT1 activity in liver/muscle, and increased p16^INK4a^+ senescent cells compared with wild‑type controls, even without analgesic treatment.
Pharmacologic mimic: Wild‑type mice receiving chronic ibuprofen or morphine (clinically relevant doses) will recapitulate the NAD+/SIRT1 deficits and senescence phenotype observed in TRPV1‑KO mice.
Rescue: Supplementation with NAD+ precursors (NR or NMN) or SIRT1 activators (e.g., SRT1720) will normalize autophagic flux and reduce senescence markers in analgesic‑treated mice, despite continued nocceptor blockade.
Human correlate: Older adults on long‑term NSAIDs/opioids will exhibit lower circulating NAD+ metabolites and higher senescence‑associated secretory phenotype (SASP) factors in plasma than age‑matched analgesic‑naïve peers, correlating with accelerated epigenetic aging clocks.

Falsifiability

If chronic analgesic administration fails to lower NAD+ or SIRT1 activity, or if NAD+ supplementation does not mitigate senescence markers in treated animals, the proposed mechanistic link would be refuted. Similarly, if TRPV1‑KO mice do not display the predicted NAD+/SIRT1 deficits, the nociceptor‑CGRP origin of the signal would be challenged.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC6790390/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC9805287/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC3529168/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC2276585/ [5] https://www.dovepress.com/less-well-known-consequences-of-the-long-term-use-of-opioid-analgesics-peer-reviewed-fulltext-article-DDDT [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC10455615/ [7] https://pmc.ncbi.nlm.nih.gov/articles/PMC11157629/

Hypothesis

Mechanistic Rationale

Nociceptor‑CGRP‑NAD+ Axis – Injured or inflamed tissue activates TRPV1+ sensory neurons, triggering CGRP release. CGRP binds its receptor (RAMP1/CLR) on perivascular macrophages, elevating intracellular cAMP and stimulating NAMPT‑mediated NAD+ salvage (see [1] for CGRP‑immune modulation).

NAD+‑SIRT1 Mitohormesis – NAD+ fuels SIRT1, which deacetylates PGC‑1α, FOXO3a, and NF‑κB, promoting mitochondrial biogenesis, antioxidant defenses, and autophagy—core effectors of mild stress‑induced hormesis ([6]).

Analgesic Interruption – NSAIDs inhibit COX‑derived prostaglandins that sensitize TRPV1; opioids directly inhibit neuronal excitability. Both blunt CGRP efflux ([2],[4]), thereby decreasing macrophage NAD+ production.

Outcome – Reduced SIRT1 activity leads to accumulated acetyl‑p53, diminished FOXO‑driven stress resistance, and impaired mitophagy, driving cellular senescence and inflammaging ([3],[5]).

Testable Predictions

In vivo: Mice with sensory‑neuron‑specific TRPV1 deletion (Nav1.8‑Cre;Trpv1^fl/fl) will show lower plasma NAD+, reduced SIRT1 activity in liver/muscle, and increased p16^INK4a^+ senescent cells compared with wild‑type controls, even without analgesic treatment.

Pharmacologic mimic: Wild‑type mice receiving chronic ibuprofen or morphine (clinically relevant doses) will recapitulate the NAD+/SIRT1 deficits and senescence phenotype observed in TRPV1‑KO mice.

Rescue: Supplementation with NAD+ precursors (NR or NMN) or SIRT1 activators (e.g., SRT1720) will normalize autophagic flux and reduce senescence markers in analgesic‑treated mice, despite continued nocceptor blockade.

Human correlate: Older adults on long‑term NSAIDs/opioids will exhibit lower circulating NAD+ metabolites and higher senescence‑associated secretory phenotype (SASP) factors in plasma than age‑matched analgesic‑naïve peers, correlating with accelerated epigenetic aging clocks.

Falsifiability